Salvage therapy for relapsed or refractory diffuse large B-cell lymphoma: Impact of prior rituximab

Haematologica

Volumn 93, Issue 12, 2008, Pages 1776-1780

  Sud, Rohit ^a   Friedberg, Jonathan W ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CARMUSTINE; CD20 ANTIBODY; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ENZASTAURIN; ETOPOSIDE; FOSTAMATINIB; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; MELPHALAN; METHYLPREDNISOLONE SODIUM SUCCINATE; OFATUMUMAB; PREDNISONE; PROTEIN KINASE SYK INHIBITOR; RITUXIMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; VELTUZUMAB; VINCRISTINE;

B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CELLULAR IMMUNITY; CHEMOSENSITIVITY; CLINICAL TRIAL; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE FREE SURVIVAL; DRUG EFFICACY; EDITORIAL; HUMAN; IMMUNOGLOBULIN DEFICIENCY; LARGE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENT DISEASE; SALVAGE THERAPY; SINGLE DRUG DOSE; STEM CELL TRANSPLANTATION; SURVIVAL TIME; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTIBODIES, MONOCLONAL; DRUG RESISTANCE, NEOPLASM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; SALVAGE THERAPY;

EID: 57349096804     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: 10.3324/haematol.2008.000984     Document Type: Editorial

References (21)

1. Anderson JR, Armitage JO, Weisenburger DD. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998;9:717-20.
2. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42.
3. Sehn LH, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-33.
4. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995;333:1540-5.
5. Martín A, Conde E, Arnan M, Canales MA, Deben G, Sancho JM, et al. on behalf of the 'Grupo Español de Linfomas/ Trasplante Autólogo de Médusa ósea' (GEL/TAMO cooperative group). R-ESHAP as salvage therapy for patients with relapsed or refractory diffuse large B-cell lymphoma: the influence of prior exposure to rituximab on outcome. A GEL/TAMO study. Haematologica 2008;93:1829-36.
6. Vellenga E, van Putten WL, van't Veer MB, Zijlstra JM, Fibbe WE, van Oers MH, et al. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial. Blood 2008;111:537-43.
7. Kewalramani T, Zelenetz AD, Nimer SD, Portlock C, Straus D, Noy A, et al. Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma. Blood 2004;103:3684-8.
8. Soussain C, Souleau B, Gabarre J, Zouabi H, Sutton L, Boccaccio C, et al. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients. Leuk Lymphoma 1999;33:543-50.
9. Giesselbrecht C, Schmitz N, Mounier N, Ma D, Trneny M, Hagberg H et al. R-ICE versus R-DHAP in relapsed patients with CD20 difuse large B-cell lymphoma (DLBCL) followed by stem cell transplantation and maintenance treatment with rituximab or not: first interim analysis on 200 patients. CORAL study. Blood (ASH Annual Meeting Abstracts), Nov 2007; 110: 517.
10. Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology Am Soc Hematol Educ Program 2005:329-34.
11. Zelenetz AD SM, Vose J, Younes A, Kaminski MS. Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine I 131 tositumomab (Bexxar). Blood 2002;100:357a.
12. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007;110:54-8.
13. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, et al. Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993;329:1219-24.
14. Vose J, Bierman P, Bociek G, Loberiza F, Enke C, Hankins J, Armitage J. Radioimmunotherapy with 131-I tositumomab enhanced survival in good prognosis relapsed and high-risk diffuse large B-cell lymphoma (DLBCL) patients receiving high-dose chemotheapy and autologous stem cell transplantation [ASCO abstract 8013]. J Clin Oncol 2007:8013.
15. Krishnan A, Nademanee A, Fung HC, Raubitschek AA, Molina A, Yamauchi D, et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008;26:90-5.
16. Khouri IF, Saliba RM, Hosing C, Okoroji GJ, Acholonu S, Anderlini P, et al. Concurrent administration of high-dose rituximab before and after autologous stem-cell transplantation for relapsed aggressive B-cell non-Hodgkin's lymphomas. J Clin Oncol 2005;23:2240-7.
17. Horwitz SM, Negrin RS, Blume KG, Breslin S, Stuart MJ, Stockerl-Goldstein KE, et al. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood 2004;103:777-83.
18. Martin P, Furman RR, Ruan J, Elstrom R, Barrientos J, Niesvizky R, et al. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma. Semin Hematol 2008;45:126-32.
19. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol 2007;25:1741-6.
20. Abramson JS, Shipp MA. Advances in the biology and therapy of diffuse large B-cell lymphoma: moving toward a molecularly targeted approach. Blood 2005;106:1164-74.
21. Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, et al. SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma. Blood 2008;111:2230-7.